Amber M Bates1, Maria Paula Gomez Hernandez1, Emily A Lanzel2, Fang Qian1,3, Kim A Brogden1. 1. Iowa Institute for Oral Health Research, College of Dentistry, University of Iowa, Iowa City, IA 52242, USA. 2. Department of Oral Pathology, Radiology and Medicine, College of Dentistry, University of Iowa, Iowa City, IA 52242, USA. 3. Division of Biostatistics and Research Design, College of Dentistry, University of Iowa, Iowa City, IA 52242, USA.
Abstract
BACKGROUND: Biomarkers like programmed death ligand-1 (PDL1) have become a focal point for immunotherapeutic checkpoint inhibition in head and neck squamous cell carcinoma (HNSCC). However, it's only part of the total immunosuppressive biomarker profile of HNSCC cells. Matrix metalloproteinases (MMPs) are enzymes that break down the basement membrane allowing cancer cells to metastasize and play an important role in the tumor microenvironment. MMPs can also activate certain cytokines, growth factors, and chemokines post-translationally. The objective of this study was to determine MMP and biomarker profiles of seven different HNSCC cell lines. METHODS: Authenticated cell lines were grown in minimal media at 1×106 viable cells/mL and incubated at 37 °C. After 24 hrs supernatants were collected, and adhering cells were lysed. Multiplex immunoassays were used to determine MMP1, MMP7, MMP9, IL-6, VEGFA, IL-1α, TNF-α, GM-CSF, IL-1RA, and IL-8 concentrations in supernatants. ELISAs were used to determine PDL1, CD47, FASL, and IDO concentrations in cell lysates. A one-way ANOVA was fit to examine log-transformed concentrations of biomarkers between seven HNSCC cell lines, and pairwise group comparisons were conducted using post- hoc Tukey's honest significance test (α=0.05). RESULTS: Significant differences (P<0.05) in MMP and biomarker concentrations were found between the seven HNSCC cell lines. For example, MMP9 was highest in SCC25 and UM-SCC99, MMP7 was highest in SCC25 and UM-SCC19, and MMP1 was highest in SCC25. CONCLUSIONS: These results suggest different patients' HNSCC cells can express distinct profiles of select biomarkers and MMPs, which could be due to metastatic stage of the cancer, primary tumor site, type of tissue the tumor originated from, or genomic differences between patients. MMP and biomarker expression profiles should be considered when choosing cell lines for future studies. The results support the reason for personalized medicine and the need to further investigate how it can be used to treat HNSCC.
BACKGROUND: Biomarkers like programmed death ligand-1 (PDL1) have become a focal point for immunotherapeutic checkpoint inhibition in head and neck squamous cell carcinoma (HNSCC). However, it's only part of the total immunosuppressive biomarker profile of HNSCC cells. Matrix metalloproteinases (MMPs) are enzymes that break down the basement membrane allowing cancer cells to metastasize and play an important role in the tumor microenvironment. MMPs can also activate certain cytokines, growth factors, and chemokines post-translationally. The objective of this study was to determine MMP and biomarker profiles of seven different HNSCC cell lines. METHODS: Authenticated cell lines were grown in minimal media at 1×106 viable cells/mL and incubated at 37 °C. After 24 hrs supernatants were collected, and adhering cells were lysed. Multiplex immunoassays were used to determine MMP1, MMP7, MMP9, IL-6, VEGFA, IL-1α, TNF-α, GM-CSF, IL-1RA, and IL-8 concentrations in supernatants. ELISAs were used to determine PDL1, CD47, FASL, and IDO concentrations in cell lysates. A one-way ANOVA was fit to examine log-transformed concentrations of biomarkers between seven HNSCC cell lines, and pairwise group comparisons were conducted using post- hoc Tukey's honest significance test (α=0.05). RESULTS: Significant differences (P<0.05) in MMP and biomarker concentrations were found between the seven HNSCC cell lines. For example, MMP9 was highest in SCC25 and UM-SCC99, MMP7 was highest in SCC25 and UM-SCC19, and MMP1 was highest in SCC25. CONCLUSIONS: These results suggest different patients' HNSCC cells can express distinct profiles of select biomarkers and MMPs, which could be due to metastatic stage of the cancer, primary tumor site, type of tissue the tumor originated from, or genomic differences between patients. MMP and biomarker expression profiles should be considered when choosing cell lines for future studies. The results support the reason for personalized medicine and the need to further investigate how it can be used to treat HNSCC.
Entities:
Keywords:
Biomarkers; cell culture techniques; head and neck squamous cell carcinoma (HNSCC); immunosuppression; matrix metalloproteinases (MMPs); tumor microenvironment
Authors: C Romagosa; S Simonetti; L López-Vicente; A Mazo; M E Lleonart; J Castellvi; S Ramon y Cajal Journal: Oncogene Date: 2011-02-07 Impact factor: 9.867
Authors: Omar Shkeir; Maria Athanassiou-Papaefthymiou; Martian Lapadatescu; Petros Papagerakis; Michael J Czerwinski; Carol R Bradford; Thomas E Carey; Mark E P Prince; Gregory T Wolf; Silvana Papagerakis Journal: Head Neck Date: 2013-01-16 Impact factor: 3.147
Authors: Carole Fakhry; William H Westra; Sigui Li; Anthony Cmelak; John A Ridge; Harlan Pinto; Arlene Forastiere; Maura L Gillison Journal: J Natl Cancer Inst Date: 2008-02-12 Impact factor: 13.506
Authors: Emily A Lanzel; M Paula Gomez Hernandez; Amber M Bates; Christopher N Treinen; Emily E Starman; Carol L Fischer; Deepak Parashar; Janet M Guthmiller; Georgia K Johnson; Taher Abbasi; Shireen Vali; Kim A Brogden Journal: Cancer Immunol Immunother Date: 2016-09-29 Impact factor: 6.968
Authors: Derek S Borgwardt; Aaron D Martin; Jonathan R Van Hemert; Jianyi Yang; Carol L Fischer; Erica N Recker; Prashant R Nair; Robinson Vidva; Shwetha Chandrashekaraiah; Ann Progulske-Fox; David Drake; Joseph E Cavanaugh; Shireen Vali; Yang Zhang; Kim A Brogden Journal: Sci Rep Date: 2014-01-29 Impact factor: 4.379
Authors: Saray Quintero-Fabián; Rodrigo Arreola; Enrique Becerril-Villanueva; Julio César Torres-Romero; Victor Arana-Argáez; Julio Lara-Riegos; Mario Alberto Ramírez-Camacho; María Elizbeth Alvarez-Sánchez Journal: Front Oncol Date: 2019-12-06 Impact factor: 6.244
Authors: Daniel J Lin; James C K Ng; Lei Huang; Max Robinson; James O'Hara; Janet A Wilson; Andrew L Mellor Journal: Clin Otolaryngol Date: 2021-05-30 Impact factor: 2.729
Authors: Christin Riess; Björn Schneider; Hanna Kehnscherper; Julia Gesche; Nina Irmscher; Fatemeh Shokraie; Carl Friedrich Classen; Elisa Wirthgen; Grazyna Domanska; Annette Zimpfer; Daniel Strüder; Christian Junghanss; Claudia Maletzki Journal: Front Immunol Date: 2020-02-14 Impact factor: 7.561